lncRNA activating regulator of DKK1Genealiases: A-ROD · LINC01468 · lnc-MBL2-4
Q-omics provides the consensus-scored LNCAROD profile across patient tissues and cancer cell-line models. LNCAROD expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, LNCAROD is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, LNCAROD RNA expression shows 15,848 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BRCA, HNSC, and GBM as cancer lineages where LNCAROD shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LNCAROD — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LNCAROD survival associations across molecular data types. LNCAROD RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LNCAROD RNA expression–survival associations across cancer types. High LNCAROD expression shows unfavorable associations in BRCA, LUAD, MESO, UCEC, KIRP and PAAD. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for LNCAROD RNA expression.
This table summarizes LNCAROD tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for LNCAROD. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LNCAROD shows higher tumor expression in HNSC, LUAD, LIHC, LUSC, BLCA and KIRC. The HNSC box plot shows higher LNCAROD RNA expression in tumor versus normal tissue (log2 FC = +2.145, t-test p < 0.001).
This table shows molecular features associated with LNCAROD in patient tissues and cancer cell lines. In patient samples, LNCAROD shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
